rejection

Managing Preanalytical Processes for Patient Safety

...es on specimen collection was not enough to reduce rejection rates for nurse phlebotomy. "You have to explain to nurses the reasons behind the procedures. Nurses and laboratory personnel have different mindsets and incorrect assumptions about each other, Wright says. "Lab staff incorrectly assumes that all n...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...osporine and corticosteroids) for theprevention of rejection in patients receiving kidney, heart andliver transplants. There are no adequate and well-controlledstudies in pregnant women. As CellCept has been shown to haveteratogenic effects in animals at subclinical doses on a bodysurface area basis, it may ca...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

...ould be recognized anddestroyed by multiple immune rejection modulators. This isn't thecase. The benefit to patients is that a reduction in therequirement for immunosuppression decreases the potential foruntoward side effects that are common with those types ofdrugs." The data indicate that GRNOPC1 cells ha...

Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD

...atory approval;delays in the approval or potential rejection of any applicationswe file with the FDA, or other health regulatory authorities; lackof progress of our research and development (including the resultsof clinical trials being conducted by us); obtaining on a timelybasis sufficient patient enrollment...

Early Results of the CellCept Spare the Nephron Study Examine Kidney Function

...liver transplant recipientsexamine ways to prevent rejection without damaging kidneys. As transplant patients ...tionrate (GFR) of their kidneys without increasing rejection rates. A total of 208 of 305 kidney transplant patients completed 12months of follow-up in this ope...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

..., resulting in 9% incidence ofacute rejection. All rejection episodes were appropriately treated.No transplanted kidneys have been lost. When all three of theISA247 dosing groups are combined, there is a 7% rate of acuterejection in the ISA247 groups compared to a 9% rate of acuterejection in the tacrolimus gr...

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007

...with LX201 for the prevention of cornealtransplant rejection were initiated in early 2007. -- A proprietary product-enabling bio-erodible polymertechnology that facilitates targeted and sustained delivery ofmolecules to the eye. For more information on Lux Biosciences, please visit thecompany's website at ww...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

...ression therapy and lower incidences ofacute organ rejection in heart transplants. Research to be presente... the first year following hearttransplant is acute rejection of the transplanted organ. Thepatient's immune system attacks the heart as if it were a foreignobjec...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

...une diseases and for use in the prevention oforgan rejection in transplantation. Isotechnika looks to become theleader in development of immunosuppressant therapies. Isotechnika'slead compound, ISA247 has successfully completed a Phase 3 Canadiantrial for the treatment of moderate to severe psoriasis. ISA247 i...

AtheroGenics Reports ARISE Trial Results for AGI-1067

...g developed for the prevention of organ transplant rejection incollaboration with Astellas. AtheroGenics also has preclinicalprograms in rheumatoid arthritis and asthma utilizing itsproprietary vascular protectant® technology. For moreinformation about AtheroGenics, please visit <a target="_blank"href=...

Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint

...ng developedfor the prevention of organ transplant rejection in collaborationwith Astellas. AtheroGenics also has preclinical programmes inrheumatoid arthritis and asthma utilizing its proprietary vascularprotectant® technology. For more information aboutAtheroGenics, please visit <a target="_blank" hr...

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis

...nflammatory events contributing to organtransplant rejection and autoimmune and related diseases.Daclizumab is ...ody is indicated for theprophylaxis of acute organ rejection in patients receiving renaltransplants. About Biogen Idec Biogen Idec creates new standards of car...